1. Jensen-Fangel S, Kirk O, Larsen L, Blaxhult A, Gerstoft J, Pedersen C, Black FT, Lundgren JD, Obel N. Saquinavir hard gel suppresses viral load insufficiently in hiv-infected patients naive to anti-retroviral therapy: a retrospective cohort study. Scand J Infect Dis 1999; 31: 489-493.
2. Jensen-Fangel S, Kirk O, Blaxhult A, Gerstoft J, Pedersen C, Black F, Lundgren JD, Obel N. The insufficient suppression of viral load by saquinavir hard gel is reversible: a retrospective cohort study. HIV Clin Trials 2001; 2: 122-127.
3. Jensen-Fangel S, Pedersen C, Larsen CS, Tauris P, Møller A, Obel N. Changing demographics in an HIV-infected population: Results from an observational cohort study in Western Denmark. Scand J Infect Dis 2001; 33: 765-770.
4. Jensen-Fangel S, Pedersen C, Larsen CS, Tauris P, Møller A, Obel N. HIV i Vestdanmark. Ugeskrift for Læger 2002; 164: 3964-67.
5. Jensen-Fangel S, Pedersen C, Larsen CS, Tauris P, Møller A, Obel N. Trends in the use of HAART in Western Denmark 1995-2000. Scand J Infect Dis 2002; 34: 460-465.
6. Jensen-Fangel S, Pedersen L, Pedersen C, Larsen CS, Tauris P, Møller A, Sørensen HT & Obel N. The Effect of Race/ethnicity on the outcome of Highly Active Antiretroviral Therapy in HIV-1 Infected Patients in West Denmark. Clin Infect Dis 2002; 35: 1541-1548.
7. Jensen-Fangel S, Pedersen C, Nielsen H, Tauris P, Møller A, Sorensen HT, Obel N. The use of saquinavir hard gel as protease inhibitor in HIV-infected patients in the early HAART-period: does it affect long-term treatment outcome? Scand J Infect Dis 2003; 35: 743-749.
8. Jensen-Fangel S, Pedersen L, Pedersen C, Larsen CS, Tauris P, Møller A, Sørensen HT, Obel N. Low Mortality in HIV-Infected Patients Starting HAART in Advance of Immunological Deterioration: A Comparison with the General Population. AIDS 2004; 18: 89-97.
9. Lohse N, Ladefoged K, Pedersen L, Jensen-Fangel S, Sørensen HT, Obel N. Low effectiveness of highly active antiretroviral therapy and high mortality in the Greenlandic HIV-infected population. Scand J Infect Dis 2004; 36: 738-42.
10. Jensen-Fangel S. The effectiveness of highly active antiretroviral therapy in HIV infected patients. Disputats. Lægeforeningens Forlag 2004.
11. Barfod T, Gerstoft J, Rodkjær L, Pedersen C, Nielsen H, Møller A, Kristensen LH, Sørensen HT, Obel N. Patients answers to simple questions about treatment satisfaction and adherence and depression are associated with failure of HAART; A cross-sectional survey. AIDS patient care and STDS 2005; 19: 317-25.
12. Lohse N, Hansen ABE, Jensen-Fangel Søren, Kronborg G, Kvinesdal B, Pedersen C, Larsen CS, Møller A, Willumsen L and Obel N. Demographics of HIV-1 infection in Denmark: Results from The Danish HIV Cohort Study. Scand J Infect Dis 2005; 37: 338-343.
13. Schmid J, Jensen-Fangel S, Valerius NH, Nielsen VR, Obel N, Herlin T, Christensen HO, Nielsen H, Obel N. Demographics in HIV-infected children in Denmark: Results from the Danish Paediatric HIV Cohort Study. Scand J Infect Dis 2005; 37: 344-349.
14. Lohse N, Obel N, Kronborg G, Laursen A, Pedersen C, Larsen CS, Kvinesdal B, Sørensen HT, Gerstoft J. Declining risk of triple-class antiretroviral drug failure in Danish HIV-infected. AIDS 2005; 20: 815-22.
15. Masquelier B, Bhaskaran K, Pillay D, Gifford R, Balestre E, Jørgensen LB, Pedersen C, Hoek L, Prins M, Balotta C, Longo B, Kücherer C, Poggensee G, Ortiz M, Romero J, Gill J, Fleury H, Porter K on behalf of the CASCADE Collaboration. Prevalence and factors associated with transmitted HIV drug resistance: the role of patient characteristics and different interpretation algorithms. JAIDS 2005; 40: 505-11.
16. Rhee SY, Kantor R, Katzenstein DA, Camacho R, Morris L, Sirivichayakul S, Jorgensen L, Brigido LF, Schapiro JM, Shafer RW; International Non Subtype B HIV-1 Working Group. HIV-1 pol mutation frequency by subtype and treatment experience: extension of the HIVseq program to seven non-B subtypes. AIDS 2006 ; 20:643-51.
17. Pillay D, Bhaskaran K, Jurriaans S, Prins M, Masquelier B, Dabis F, Gifford R, Nielsen C, Pedersen C, Balotta C, Rezza G, Ortiz M, de Mendoza C, Kucherer C, Poggensee G, Gill J, Porter K; CASCADE Virology Collaboration. The impact of transmitted drug resistance on the natural history of HIV infection and response to first-line therapy. AIDS 2006; 20: 21-8.
18. Hansen ABE, Lindegaard B, Obel N, Andersen O, Nielsen H, Gerstoft J. Pronounced lipoatrophy in HIV-infected men on more than six years of HAART compared with background population. HIV Med 2006; 7: 38-45.
19. Lohse N, Kronborg G, Gerstoft J, Larsen CS, Pedersen G, Pedersen C, Sørensen HT, Obel N. Virological control during the first 6-18 months after initiating highly active antiretroviral therapy as a predictor for outcome in HIV-infected patients: A Danish population-based 6 years follow-up study. Clin Infect Dis 2006; 42: 136-144.
20. Barfod T, Sørensen TS, Nielsen H, Rodkjær L, Obel N. “Simply forgot” is HT the most frequently stated reason for missed doses of HAART irrespective of degree of adherence. HIV Med 2006; 7: 285-290.
21. Nicolai Lohse. HIV in Denmark and Greenland, 1995-2004. The effect of highly antiretroviral therapy and characteristics of the HIV-infected population: An observational study. PhD afhandling.
22. Weis N, Lindhardt BØ, Kronborg G, Hansen ABE, Laursen AL, Christensen PB, Nielsen H, Møller A, Sørensen HT, Obel N. Impact of HCV Co-infection on Response to HAART and Outcome in HIV-Infected Individuals: A nation-wide cohort study. Clin Infect Dis 2006, 42: 1481-87.
23. Lohse N, Obel N, Kronborg G, Jørgensen LB, Pedersen C, Larsen CS, Kvinesdal B, Sørensen HT, Gerstoft J. Declining prevalence of HIV infected individuals at risk of transmitting resistant HIV in Denmark during the period 1995-2003. Antivir Ther 2006; 11, 591-600.
24. Hansen ABE. Non-HIV determinants of outcome in Danish HIV infected patients: impact of study participation, body fat distribution and family related factors. PhD afhandling.
25. Hansen ABE, Gerstoft J, Kronborg G, Pedersenc, Sørensen HT, Obel N. Mortality in siblings of patients co-infected with HIV and hepatitis C virus. J Infect Dis 2007; 195: 230-235.
26. Lohse N, Hansen ABE, Pedersen G, Kronborg G, Gerstoft J, Sørensen HT, Væth M, Obel N. Median survival and age-specific mortality of HIV-infected individuals compared with the general population: A Danish population-based cohort study. Ann of Intern Med 2007; 146: 87-95.
27. Obel N, Thomsen HF, Kronborg G, Larsen CS, Hildebrandt PR, Sørensen HT, Gerstoft J. Highly active antiretroviral therapy and hospitalization for ischemic heart disease in HIV-infected Patients: A population-based cohort study. Clin Infect Dis 2007; 44: 1625-31
28. Bracher L,Valerius NH, Rosenfeldt V, Herlin T, Fisker N, Nielsen H, Obel N. Long-term Effectiveness of Highly Active Antiretroviral Therapy in Perinatally HIV-Infected Children in Denmark. Scand J Infect Dis 2007; 39: 799-804.
29. Rasmussen LD, Gerstoft J, Kronborg G, Larsen CS, Pedersen G, Obel N. Mortality after myocardial infarction in HIV-infected patients who have initiated HAART. AIDS 2007, 21: 873-875.
30. Madsen TV, Leitner T, Lohse N, Obel N, Ladefoged K, Gerstoft J, Petersen AN, Nielsen C, Jørgensen LB. Introduction of HIV-1 into an isolated population: Molecular epidemiologic study from Greenland. AIDS Res Human Retroviruses 2007; 23: 675-81.
31. Hansen ABE, Gerstoft J, Kirk O, Mathiesen L, Pedersen C, Nielsen H, Jensen-Fangel S, Sørensen HT Obel N. Unmeasured confounding caused slightly better response to HAART within than outside a randomized controlled trial. J Clin Epidemiol 2008; 61:87-94.
32. Hansen ABE, Lohse N, Gerstoft J, Kronborg G, Laursen A, Pedersen C, Sørensen HT, Obel N. Cause-specific excess mortality in siblings of patients coinfected with HIV and hepatitis C virus. PLOS One 2007; 2:e738.
33. Lohse N, Jørgensen LB, Kronborg G, Møller A, Kvinesdal B, Sørensen HT, Obel N, Gerstoft J and The Danish HIV Cohort Study. Genotypic drug resistance and long-term mortality in patients with triple-class antiretroviral drug failure. Antivir Ther 2007; 12: 909-917 .
34. Lohse N, Hansen ABE, Pedersen G, Kronborg G, Gerstoft J, Sørensen HT, Væth M, Obel N. Forventet overlevelse blandt personer med og uden HIV-infektion i Danmark 1995-2005. Ugeskrift for Læger 2007; 169: 2529-32.
35. Lohse N, Hansen ABE, Gerstoft J, Obel N. Improved survival in HIV-infected persons: consequences and perspectives. J Antimicrob Chem 2007; 60: 461-3.
36. Høgh S, Lohse N, Hansen ABE, Gerstoft J, Kronborg G, Larsen CS, Pedersen C, Pedersen G, Laursen AL, Kvinesdal B, Møller A, Obel N. Ændring i immunstatus blandt nydiagnosticerede HIV patienter 1995-2005. Ugeskrift for Læger 2008; 170: 740-44.
37. Fellay J, Shianna KV, Ge, D, Colombo S, Ledergerber B, Weale M, Zhang K, Gumbs C, Castagna A, Cossarizza A, Cozzi-Lepri A, De Luca A, Easterbrook P, Francioli P, Mallal S, Martinez-Picado J, Miro JM, Obel N, Smith JP, Wyniger J, Descombes P, Antonarakis SE, Letvin NL, McMichael AJ, Haynes BF, Telenti A, Goldstein DB. Identification of Major Determinants of the Host Control of HIV-1 through a Whole-Genome Association Study. Science 2007; 317: 944-947.
38. Lohse N, Ladefoged K, Obel N. Implementation and effectiveness of antiretroviral therapy in Greenland. Emerg Infect Dis 2008; 14: 56-9.
39. Sabin CA, Smith CJ, d’Arminio Monforte A, Battegay M, Gabiano C, Galli L, Geelen S, Gibb D, Guiguet M, Judd A, Leport C, Dabis F, Pantazis N, Porter K, Raffi F, Thorne C, Torti C, Walker S, Warszawski J, Wintergerst U, Chêne G, Lundgren J. Response to combination antiretroviral therapy: variation by age. AIDS 2008; 22: 1463–1473.
40. Omland LH, Weis N, Skinhoj N, Laursen AL, Christensen PB, Nielsen H, Møller A, Engsig F, Sorensen HT, Obel N. Impact of HBV Coinfection on Response to HAART and Outcome in HIV-Infected Individuals: A nationwide cohort study. HIV Med 2008; 9: 300–306.
41. Obel N, Reinholdt H, Omland LH, Engsig F, Sørensen HT, Hansen ABE. Completeness of HIV and Hepatitis B and C Co-infection in the Danish National Hospital Registry, 1995-2004. BMC Medical Research Methodology 2008; 8: 25.
42. Madsen TV, Lohse N, Jensen ES, Obel N, Ladefoged K, Gerstoft J, Petersen AB, Nielsen C, Jørgensen LB. Short communication: high prevalence of drug-resistant human immunodeficiency virus type 1 in treatment-naïve patients in Greenland. AIDS Res Hum Retroviruses 2008; 24: 1073-7.
43. Omland LH, Jepsen P, Skinhøj P, Jørgensen HL, Münster A-MB, Bangsborg JM, Fenger M, Sørensen HT, Obel N. The impact of HIV-1 coinfection on long-term mortality in patients with Hepatitis C: A population-based cohort study. HIV Med 2009; 10: 65-71.
44. Søgaard OS, Lohse N, Gerstoft J, Kronborg G, Østergaard L, Pedersen C, Pedersen G, Sørensen HT, Obel N. Hospitalisation for pneumonia among individuals with and without HIV, 1995-2007: A Danish population-based nationwide cohort study. Clin Infect Dis 2008: 47; 1345-53.
45. Obel N, Engsig FN, Rasmussen LD, Larsen MV, Omland LH, Sørensen HT. Cohort profile: The Danish HIV Cohort Study. Int J Epidemiol 2009; 38: 1202-6.
46. Engsig F, Hansen ABE, Omland LH, Kronborg G, Gerstoft J, Laursen AL, Pedersen C, Mogensen CB, Nielsen L, Obel N. Incidence, clinical presentation and outcome of progressive multifocal leucoencephalopathy in HIV infected patients in the HAART era: a nationwide cohort study. J Infect Dis 2009; 199: 77-83.
47. Hansen BR, Petersen J, Haugaard SB, Madsbad S, Obel N, Suzuki Y, Andersen O. The prevalence of metabolic syndrome in Danish patients with HIV: the effect of antiretroviral therapy. HIV Med 2009; 10: 378-87.
48. Omland LH, Jepsen P, Weis N, Christensen PB, Laursen AL, Nielsen H, Krarup H, Sørensen HT, Obel N. Mortality in HIV-infected injection drug users with active versus cleared HCV-infection: A population-based cohort study. J Viral Hepat 2010; 17: 261-8.
49. Banke S, Lillemark MR, Gerstoft J, Obel N, Jørgensen LB. Positive Selection Pressure Introduces Secondary Mutations at the Gag Cleavages Sites in HIV-1 Harboring Major Protease Resistance Mutations. J Virol 2009; 83: 8916-24.
50. Audelin A, Lohse N, Obel N, Gerstoft J, Jørgensen LB. The incidence rate of HIV type-1 drug resistance in patients on antiretroviral therapy: a nationwide population-based Danish cohort study 1999-2005. Antivir Ther 2009; 14: 995-1000.
51. Fellay J, Ge D, Shianna KV, Colombo S, Ledergerber B, Cirulli1 ET, Urban TJ, Zhang K, Gumbs CE, Smith JP, Castagna A, Cozzi-Lepri A, De Luca A, Easterbrook P, Günthard HF, Mallal S, Mussini C, Dalmau J, Martinez-Picado J, Miro JM, Obel N, Wolinsky SM, Martinson JJ, Detels R, Margolick JB, Jacobson LP, Descombes P, Antonarakis SE, Beckmann JS, O’Brien SJ, Letvin NL, McMichael AJ, Haynes BF, Carrington M, Feng S, Telenti A & Goldstein DB. Common Genetic Variation and the Control of HIV-1 in Humans. PLoS Genetics 2009; 5: e1000791.
52. Bohilus J, Schmidlin K, Costagliola D, Fätkenheuer G, May M, Caro Murillo AM, Mocroft A, Bonnet F, Clifford G, Karafoulidou A, Miro JM, Lundgren J, Miro JM, Chene G, Egger M.. Incidence and risk factors of HIV-related non-Hodgkin's lymphoma in the era of combination antiretroviral therapy: a European multicohort study. Antivir Ther 2009; 14: 1065-74.
53. Bohilus J, Schmidlin K, Costagliola D, Fätkenheuer G, May M, Caro Murillo AM, Mocroft A, Bonnet F, Clifford G, Touloumi G, Miro JM, Chene G, Lundgren J, Egger M. Prognosis of HIV-associated non-Hodgkin lymphoma in patients starting combination antiretroviral therapy. AIDS 2009; 23: 2029-37.
54. Obel N, Farkas D, Kronborg G, Larsen CS, Pedersen G, Riis A, Pedersen C, Gerstoft J, Sørensen HT. Abacavir and risk of myocardial infarction in HIV infected patients on HAART: A population-based nationwide cohort study. HIV Med 2010; 11: 130-6.
55. Søgaard OS, Lohse N, Gerstoft J, Kronborg G, Østergaard L, Pedersen C, Pedersen G, Sørensen HT, Obel N. Mortality after Hospitalization for Pneumonia among Individuals with HIV, 1995-2008: A Danish Cohort Study. PLoS One 2009; 4: e7022.
56. Engsig FN, Hansen ABE, Gerstoft J, Kronborg G, Larsen CS, Obel N. Inpatient admissions and outpatient visits in persons with and without HIV infection in Denmark, 1995–2007. AIDS 2010; 28: 457-61.
57. Larsen MV, Omland LH, Gerstoft J, Larsen CS, Jensen J, Obel N, Kronborg G. Impact of injecting drug use on mortality in Danish HIV infected patients: a nationwide population based cohort study. Addiction 2010; 105: 529-35.
58. Engsig FN, Omland LH, Larsen MV, Rasmussen LD, Qvist T, Gerstoft J, Obel N. Risk of high level viraemia in HIV infected patients on successful antiretroviral treatment for more than six months. HIV Med 2010; 11: 457-61.
59. Lodwick R, Costagliola D, Reiss P, Torti C, Teira R, Dorrucci M, Ledergerber B, Mocroft A, Podzamczer D, Cozzi-Lepri A, Obel N, Masquelier B, Staszewski S, Garcia F, De Wit S, Castagna A, Antinori A, Judd A, Ghosn J, Touloumi G, Mussini C, Duval X, Ramos J, Meyer L, Warsawski J, Thorne C, Masip J, Pérez-Hoyos S, Pillay D, van Sighem A, Lo Caputo S, Günthard H, Paredes R, De Luca A, Paraskevis D, Fabre-Colin C, Kjaer J, Chêne G, Lundgren JD, Phillips AN. Triple-class virologic failure in HIV-infected patients undergoing antiretroviral therapy for up to 10 years. Arch Intern Med 2010; 170: 410-9.
60. Rasmussen LD, Omland LH, Pedersen C, Gerstoft J, Kronborg G, Jensen J, Obel N. Risk of myocardial infarction in parents of HIV-infected individuals: a population-based Cohort Study. BMC Infect Dis 2010; 10: 169.
61. Mocroft A, Reiss P, Kirk O, Mussini C, Girardi E, Morlat P, Stephan C, De Wit S, Doerholt K, Ghosn J, Bucher HC, Lundgren JD, Chene G, Miro JM, Furrer H. Is it safe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count <200 cells/microL? Clin Infect Dis 2010; 51: 611-9.
62. Lodwick RK, Sabin CA, Porter K, Ledergerber B, Sighem Av, Cozzi-Lepri A, Khaykin P, Mocroft A, Jacobson L, Wit Sd, Obel N, Castagna A, Wasmuth JC, Gill J,, Klein B, Gange S, Riera M, Mussini C, Gutiérrez F, Touloumi G, Carrieri P, Guest JL, Brockmeyer NH, Phillips. Death rates in HIV-positive antiretroviral-naive patients with CD4 count greater than 350 cells per microL in Europe and North America: a pooled cohort observational study. Lancet 2010; 376: 340-5.
63. Engsig FN, Gerstoft J, Kronborg G, Larsen CS, Pedersen G, Audelin AM, Jørgensen LB, Obel N. Clinical, virological and immunological responses in Danish HIV patients receiving raltegravir as part of a salvage regimen. Clin Epidemiol 2010; 2: 145-51.
64. Larsen MV, Omland LH, Gerstoft J, Røge BT, Larsen CS, Obel N, Kronborg G. Impact of injecting drug use on response to highly active antiretroviral treatment in HIV-1 infected patients: a nationwide population-based cohort-study. Scand J Infect Dis 2010; 42:917-23.65. Engsig FN, Gerstoft J, Kronborg G, Larsen CS, Pedersen G, Røge B, Jensen J, Nielsen LN, Obel N. Long-term mortality in HIV patients virally suppressed for more than three years with incomplete CD4 recovery: a cohort study. BMC Infect Dis 2010; 10:318.66. Qvist T, Engsig F, Kronborg G, Larsen CS, Røge B, Gerstoft J, Obel N. Predictors of unsafe sex among HIV patients in Denmark: A population-based cohort study. Scand J Infect Dis 2011; 43: 181-87.
67. Mens H, Kearney M, Wiegand A, Shao W, Schønning K, Gerstoft J, Obel N, Maldarelli F, Mellors JW, Benfield T, Coffin JM. HIV-1 continues to replicate and evolve in patients with natural control of HIV infection. J Virol 2010; 84: 12971-81.68. Lescure FX, Omland LH, Engsig FN, Roed C, Gerstoft J, Pialoux G, Kronborg G, Larsen CS, Obel N. Incidence and impact on mortality of severy neuro-cognitive disorders in persons with and without HIV: a Danish nationwide cohort study. Clin Infect Dis 2011; 52: 235-43.69. Lillemark MR, Gerstoft J, Obel N, Kronborg G, Pedersen C, Jørgensen LB, Madsen TV, Katzenstein TL. Characterization of HIV-1 from patients with virological failure to a boosted protease inhibitor regimen. J Med Virol 2011; 83: 377-83.70. Wittkop L, Günthard HF, Wolf F, Dunn D, Cozzi-Lepri A, Luca A, Kücherer C, Obel N, Wyl V, Masquelier B, Stephan C, Torti C, Antinori A, García F, Judd A, Porter K, Thiébaut R, Castro H, Sighem AI, Colin C, Kjaer J, Lundgren JD, Paredes R, Pozniak A, Clotet B, Phillips A, Pillay D, Chêne G. Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV. Lancet Infect Dis 2011;11:363-71.71. Bohlius J, Schmidlin K, Boue F, Faetkenheuer G, May M, Caro-Murillo AM, Mocroft A, Bonnet F, Clifford G, Paparizos V, Miro JM, Obel N, Prins M, Chene G, Egger M. HIV-1-related Hodgkin lymphoma in the era of combination antiretroviral therapy: incidence and evolution of CD4+ T-cell lymphocytes. Blood 2011; 117:6100-8.
72. Taarnhøj GA, Engsig FN, Ravn P, Johansen IS, Larsen CS, Røge B, Andersen AB, Obel N. Incidence, risk factors and mortality of tuberculosis in Danish HIV patients 1995-2007. BMC Pulm Med 2011;11:26.
73. Evangelou E, Fellay J, Colombo S, Martinez-Picado J, Obel N, Goldstein DB, Telenti A, Ioannidis JP. Impact of phenotype definition on genome-wide association signals: empirical evaluation in HIV-1 infection. Am J Epidemiol 2011;173:1336-42.74. Rasmussen LD, Engsig FN, Christensen H, Gerstoft J, Kronborg G, Pedersen C, Obel N. Risk of cerebrovascular events in persons with and without HIV: a Population-Based Cohort Study. AIDS 2011;25:1637-46.
75. Lohse N, Gerstoft J, Kronborg G, Larsen CS, Pedersen C, Pedersen G, Nielsen L, Sørensen HT, Obel N. Comorbidity Acquired before HIV Diagnosis and Mortality in HIV-infected and Uninfected Persons: A Danish population-based study. J Acquir Immune Defic Syndr 2011;57:334-9.
76. Castro H, Judd A, Gibb DA, Butler K, Lodwick RK, Sighem A, Ramos JT, Warsawski J, Thorne C, Noguera-Julian N, Obel N, Costagliola D, Tookey PA, Colin C, Kjaer J, Grarup J, Chene G, Phillips A. Risk of triple class virologic failure in children with HIV: a retrospective cohort study. Lancet 2011;377:1580-7.
77. Engsig FN, Gerstoft J, Kronborg G, Larsen CS, Pedersen G, Pdersen C, Obel N. Head and neck cancer in HIV patients and their parents: A Danish cohort study. Clin Epidemiol 2011;3:217-27.
78. Engsig FN, Kronborg G, Larsen CS, Pedersen G, Pedersen C, Gerstoft, Obel N. Lung cancer in HIV patients and their parents: A Danish cohort study. BMC Cancer 2011;11:272.
79. Audelin AM, Gerstoft J, Obel N, Mathiesen L, Laursen A, Pedersen C, Nielsen H, Jensen J, Nielsen L, Nielsen C, Jørgensen LB. Molecular Phylogenetics of Transmitted Drug Resistance in Newly Diagnosed HIV Type 1 Individuals in Denmark, a Nation-Wide Study. AIDS Res Hum Retroviruses. 2011;27:1283-90.
80. Rasmussen LD, Kessel L, Pedersen C, Gerstoft J, Kronborg G, Obel N. Risk of cataract surgery in HIV-infected individuals: A Danish nationwide population-based study. Clin Infect Dis 2011;53:1156-63.
81. Larsen M, Harboe ZB, Ladelund S, Skov R, Gerstoft J, Pedersen C, Larsen CS, Obel N, Kronborg G, Benfield T. Major but differential decline in incidence of Staphylococcus aureus bacteraemia in HIV-infected individuals from 1995 to 2007: a nation-wide cohort study. HIV Med 2012;13:45-53.82. Helleberg M, Pedersen C, Gerstoft J, Kronborg G,Obel N. Late presenters, repeated testing and missedopportunities in a nationwide Danish HIV cohort. Scand J Infect Dis 2011 Nov 8 Epub ahead of print. 83. Hansen AB, Gerstoft J, Kronborg G, Larsen CS, Pedersen C, Pedersen G, Obel N. Incidence of low and high-energy fractures in persons with and without HIV infection: a Danish population-based cohort study. AIDS. 2012;28:285-93.84. Helleberg M, Engsis FN, Kronborg G, Larsen CS, Pedersen G, Pedersen C, Gerstoft J, Obel N. Retention in a public health care system with free access to treatment: a Danish nationwide HIV cohort study. AIDS. 2011 Dec 7 Epub ahead of print. 85. Søgaard OS, Lohse N, Ostergaard L, Kronborg G, Røge B, Gerstoft J, Sørensen HT, Obel N. Morbidity and Risk of Subsequent Diagnosis of HIV: A Population Based Case Control Study Identifying Indicator Diseases for HIV Infection. PLoS One. 2012;7:e32538.86. Petersen TS, Andersen SE, Gerstoft J, Thorsteinsson K, Larsen CS, Pedersen G, Pedersen C, Obel N. Adherence to national guidelines for initiation of antiretroviral regimens in HIV patients: a Danish nationwide study. Brit J Clin Pharmacol In press.
87. Costagliola D, Lodwick R, Ledergerber B, Torti C, Sighem A, Podzamczer D, Mocroft A, Dorrucci M, Masquelier B, Luca A, Jansen K, Wit S, Obel N, Fätkenheuer G, Touloumi G, Mussini C, Castagna A, Stephan C, García F, Zangerle R, Duval X, Perez-Hoyos S, Meyer L, Ghosn J, Fabre-Colin C, Kjaer J, Chêne G, Grarup J, Phillips A. Trends over calendar time in virological and clinical outcomes in HIV-1 infected people with virologic failure of drugs from the three original antiretroviral drug classes: an observational cohort study. Lancet Infect Dis In press.
88. Lewden C, Bouteloup V, Wit SDE, Sabin C, Mocroft A, Wasmuth JC, Sighem A, Kirk O, Obel N, Panos G, Ghosn J, Dabis F, Mary-Krause M, Leport C, Hoyos SP, Sobrino-Vegas P, Stephan C, Castagna A, Antinori A, Monforte A, Torti C, Mussini C, Isern V, Calmy A, Teira R, Egger M, Grarup J, Chêne G. All-cause mortality in treated HIV-infected adults compared to the general population in a large European observational cohort study collaboration. Int J Epidemiol In press.
89. Obel N, Omland LH, Kronborg G, Larsen CS, Pedersen C, Pedersen G, Sørensen HT, Gerstoft J. Impact of non-HIV and HIV risk factors on survival in HIV-infected patients on HAART: A population-based nationwide cohort study. PLoS One 2011; e22698.
90. Nakagawa F, Lodwick R, Costagliola D, Sighem A, Torti C, Podzamczer D, Mocroft A, Ledergerber B, Dorrucci M, Cozzi-Lepri A, Jansen K, Masquelier B, García F, Wit S, Stephan C, Obel N, Fätkenheuer G, Castagna A, Sambatakou H, Mussini C, Ghosn J, Zangerle R, Duval X, Meyer L, Perez-Hoyos S, Fabre-Colin C, Kjaer J, Chene G, Garup J, Phillips A. Calendar time trends in the incidence and prevalence of triple-class virologic failure in antiretroviral drug experienced people with HIV in Europe. J AIDS In press.91. Mette Vang Larsen. HIV Infection and Injection Drug Use in Denmark - Studies on Morbidity and Mortality. PhD thesis 2011.92. Lars Haukali Omland. Mortality in patients coinfected with HIV and viral hepatitis B and C in Denmark. PhD thesis 2011.93. Anne Margrethe Audelin. Molecular-epidemiological studies of HIV-1 and antiretroviral resistance in Denmark. PhD thesis 2011.